FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016173035> ?p ?o ?g. }

• W2016173035 endingPage "384" @default.
• W2016173035 startingPage "377" @default.
• W2016173035 abstract "Heptaplatin (HTP), a newly developed platinum analog, has been approved for the treatment of gastric cancers in South Korea. In this study we explored the potential of HTP for the treatment of head and neck squamous cell cancers (HNSCC). The anti-proliferative activity of HTP was evaluated in FaDu, a human HNSCC cell line. Combinations of HTP with 5-fluorouracil (5-FU) or paclitaxel (PTX) were determined using combination indexes, and were compared with combinations of cisplatin and 5-FU or PTX. In order to evaluate the transport of HTP into tumor tissue, its penetration through multicell layers (MCLs) of cancer cells was measured. Cisplatin+5-FU and HTP+5-FU showed additive to antagonistic interactions. In terms of the HTP+paclitaxel combination, HTP showed antagonism and additivity at the 50 and 80% growth inhibition levels, respectively. An additive interaction was obtained and apoptosis was increased by 2-fold at both inhibition levels when the combinatorial PTX dose was reduced to 1/10. HTP, but not cisplatin or oxaliplatin (L-OHP), maintained its anti-proliferative activity after MCL penetration at clinically relevant concentrations, which can be attributed to lower protein binding of HTP. In conclusion, the present study suggests that low-dose PTX may sensitize tumor cells to HTP. HTP also showed greater penetration through multilayers of tumor cells compared to cisplatin and L-OHP, which may be an important characteristic for solid tumor treatment. Overall, the present study supports the clinical development of HTP in combination with low-dose PTX against HNSCC." @default.
• W2016173035 created "2016-06-24" @default.
• W2016173035 creator A5009835808 @default.
• W2016173035 creator A5031986653 @default.
• W2016173035 creator A5042403211 @default.
• W2016173035 creator A5077999831 @default.
• W2016173035 creator A5085525914 @default.
• W2016173035 creator A5088875334 @default.
• W2016173035 date "2006-04-01" @default.
• W2016173035 modified "2023-10-14" @default.
• W2016173035 title "Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro" @default.
• W2016173035 cites W1971330405 @default.
• W2016173035 cites W1983914017 @default.
• W2016173035 cites W1984728878 @default.
• W2016173035 cites W1989788105 @default.
• W2016173035 cites W2010140224 @default.
• W2016173035 cites W2024955764 @default.
• W2016173035 cites W2031883790 @default.
• W2016173035 cites W2041868559 @default.
• W2016173035 cites W2045678638 @default.
• W2016173035 cites W2051658829 @default.
• W2016173035 cites W2059912197 @default.
• W2016173035 cites W2065975104 @default.
• W2016173035 cites W2066312401 @default.
• W2016173035 cites W2067758224 @default.
• W2016173035 cites W2070823032 @default.
• W2016173035 cites W2071057679 @default.
• W2016173035 cites W2073098220 @default.
• W2016173035 cites W2073112634 @default.
• W2016173035 cites W2075938486 @default.
• W2016173035 cites W2077945404 @default.
• W2016173035 cites W2106893957 @default.
• W2016173035 cites W2107890342 @default.
• W2016173035 cites W2157780732 @default.
• W2016173035 cites W2312298468 @default.
• W2016173035 doi "https://doi.org/10.1097/01.cad.0000205033.08838.c7" @default.
• W2016173035 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16549994" @default.
• W2016173035 hasPublicationYear "2006" @default.
• W2016173035 type Work @default.
• W2016173035 sameAs 2016173035 @default.
• W2016173035 citedByCount "27" @default.
• W2016173035 countsByYear W20161730352012 @default.
• W2016173035 countsByYear W20161730352013 @default.
• W2016173035 countsByYear W20161730352014 @default.
• W2016173035 countsByYear W20161730352015 @default.
• W2016173035 countsByYear W20161730352016 @default.
• W2016173035 countsByYear W20161730352017 @default.
• W2016173035 countsByYear W20161730352018 @default.
• W2016173035 countsByYear W20161730352021 @default.
• W2016173035 countsByYear W20161730352022 @default.
• W2016173035 countsByYear W20161730352023 @default.
• W2016173035 crossrefType "journal-article" @default.
• W2016173035 hasAuthorship W2016173035A5009835808 @default.
• W2016173035 hasAuthorship W2016173035A5031986653 @default.
• W2016173035 hasAuthorship W2016173035A5042403211 @default.
• W2016173035 hasAuthorship W2016173035A5077999831 @default.
• W2016173035 hasAuthorship W2016173035A5085525914 @default.
• W2016173035 hasAuthorship W2016173035A5088875334 @default.
• W2016173035 hasConcept C121608353 @default.
• W2016173035 hasConcept C126322002 @default.
• W2016173035 hasConcept C185592680 @default.
• W2016173035 hasConcept C190283241 @default.
• W2016173035 hasConcept C202751555 @default.
• W2016173035 hasConcept C2776530083 @default.
• W2016173035 hasConcept C2776694085 @default.
• W2016173035 hasConcept C2776833033 @default.
• W2016173035 hasConcept C2776999253 @default.
• W2016173035 hasConcept C2777292972 @default.
• W2016173035 hasConcept C2778239845 @default.
• W2016173035 hasConcept C2779707156 @default.
• W2016173035 hasConcept C2780456651 @default.
• W2016173035 hasConcept C2780962732 @default.
• W2016173035 hasConcept C502942594 @default.
• W2016173035 hasConcept C526805850 @default.
• W2016173035 hasConcept C55493867 @default.
• W2016173035 hasConcept C71924100 @default.
• W2016173035 hasConcept C98274493 @default.
• W2016173035 hasConceptScore W2016173035C121608353 @default.
• W2016173035 hasConceptScore W2016173035C126322002 @default.
• W2016173035 hasConceptScore W2016173035C185592680 @default.
• W2016173035 hasConceptScore W2016173035C190283241 @default.
• W2016173035 hasConceptScore W2016173035C202751555 @default.
• W2016173035 hasConceptScore W2016173035C2776530083 @default.
• W2016173035 hasConceptScore W2016173035C2776694085 @default.
• W2016173035 hasConceptScore W2016173035C2776833033 @default.
• W2016173035 hasConceptScore W2016173035C2776999253 @default.
• W2016173035 hasConceptScore W2016173035C2777292972 @default.
• W2016173035 hasConceptScore W2016173035C2778239845 @default.
• W2016173035 hasConceptScore W2016173035C2779707156 @default.
• W2016173035 hasConceptScore W2016173035C2780456651 @default.
• W2016173035 hasConceptScore W2016173035C2780962732 @default.
• W2016173035 hasConceptScore W2016173035C502942594 @default.
• W2016173035 hasConceptScore W2016173035C526805850 @default.
• W2016173035 hasConceptScore W2016173035C55493867 @default.
• W2016173035 hasConceptScore W2016173035C71924100 @default.
• W2016173035 hasConceptScore W2016173035C98274493 @default.
• W2016173035 hasIssue "4" @default.
• W2016173035 hasLocation W20161730351 @default.

• next